Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 Infection

The pandemic of coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has become a global challenge to public health. While its typical clinical manifestations are respiratory disorders, emerging evidence of cardiovascular complications indicates the adverse interaction between SARS-CoV-2 infec...

Full description

Bibliographic Details
Main Authors: Ya Liu, Hai-Gang Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2020.629413/full
id doaj-2437708adb844bc8acb3d4602c822c7f
record_format Article
spelling doaj-2437708adb844bc8acb3d4602c822c7f2021-01-20T06:48:56ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-01-01710.3389/fmed.2020.629413629413Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 InfectionYa LiuHai-Gang ZhangThe pandemic of coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has become a global challenge to public health. While its typical clinical manifestations are respiratory disorders, emerging evidence of cardiovascular complications indicates the adverse interaction between SARS-CoV-2 infection and cardiovascular outcomes. Given that viral infection has emerged as an additional risk factor for atherosclerosis, in this paper, we attempt to clarify the susceptibility to new-onset atherosclerosis in individuals infected with SARS-CoV-2. Mechanistically, serving as functional receptors for SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2) mediates SARS-CoV-2 infection of endothelial cells (ECs) directly, leading to endothelial dysfunction and dysregulation of the renin-angiotensin system (RAS). In addition, high expression of CD147, an alternative receptor, and activation of the NLRP3 inflammasome may also contribute to atherosclerosis in the context of COVID-19. More importantly, SARS-CoV-2 attacks the immune system, which results in excessive inflammation and perpetuates a vicious cycle of deteriorated endothelial dysfunction that further promotes inflammation. The alterations in the blood lipid profile induced by COVID-19 should not be ignored in assessing the predisposition toward atherosclerosis in victims of COVID-19. A better understanding of the underlying mechanisms of SARS-CoV-2 infection and the long-term monitoring of inflammatory factors and endothelial function should be considered in the follow-up of patients who have recovered from COVID-19 for early detection and prevention of atherosclerosis.https://www.frontiersin.org/articles/10.3389/fmed.2020.629413/fullCOVID-19SARS-CoV-2atherosclerosisendothelial dysfunctioninflammationangiotensin-converting enzyme 2
collection DOAJ
language English
format Article
sources DOAJ
author Ya Liu
Hai-Gang Zhang
spellingShingle Ya Liu
Hai-Gang Zhang
Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 Infection
Frontiers in Medicine
COVID-19
SARS-CoV-2
atherosclerosis
endothelial dysfunction
inflammation
angiotensin-converting enzyme 2
author_facet Ya Liu
Hai-Gang Zhang
author_sort Ya Liu
title Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 Infection
title_short Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 Infection
title_full Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 Infection
title_fullStr Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 Infection
title_full_unstemmed Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 Infection
title_sort vigilance on new-onset atherosclerosis following sars-cov-2 infection
publisher Frontiers Media S.A.
series Frontiers in Medicine
issn 2296-858X
publishDate 2021-01-01
description The pandemic of coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has become a global challenge to public health. While its typical clinical manifestations are respiratory disorders, emerging evidence of cardiovascular complications indicates the adverse interaction between SARS-CoV-2 infection and cardiovascular outcomes. Given that viral infection has emerged as an additional risk factor for atherosclerosis, in this paper, we attempt to clarify the susceptibility to new-onset atherosclerosis in individuals infected with SARS-CoV-2. Mechanistically, serving as functional receptors for SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2) mediates SARS-CoV-2 infection of endothelial cells (ECs) directly, leading to endothelial dysfunction and dysregulation of the renin-angiotensin system (RAS). In addition, high expression of CD147, an alternative receptor, and activation of the NLRP3 inflammasome may also contribute to atherosclerosis in the context of COVID-19. More importantly, SARS-CoV-2 attacks the immune system, which results in excessive inflammation and perpetuates a vicious cycle of deteriorated endothelial dysfunction that further promotes inflammation. The alterations in the blood lipid profile induced by COVID-19 should not be ignored in assessing the predisposition toward atherosclerosis in victims of COVID-19. A better understanding of the underlying mechanisms of SARS-CoV-2 infection and the long-term monitoring of inflammatory factors and endothelial function should be considered in the follow-up of patients who have recovered from COVID-19 for early detection and prevention of atherosclerosis.
topic COVID-19
SARS-CoV-2
atherosclerosis
endothelial dysfunction
inflammation
angiotensin-converting enzyme 2
url https://www.frontiersin.org/articles/10.3389/fmed.2020.629413/full
work_keys_str_mv AT yaliu vigilanceonnewonsetatherosclerosisfollowingsarscov2infection
AT haigangzhang vigilanceonnewonsetatherosclerosisfollowingsarscov2infection
_version_ 1724331243553685504